Home >> Top News >> NeoGenomics to host molecular symposium

NeoGenomics to host molecular symposium

Print Friendly, PDF & Email

Dec. 28, 2017NeoGenomics will host a symposium, “NGS for Clinicians and Pathologists: An Overview of Principles and Clinical Applications,” Feb. 23–24, 2018 at Laguna Cliffs Marriott Resort and Spa, Dana Point, Calif.

Objectives of the symposium are to simplify next-generation sequencing for clinicians and pathologists with discussion of its advantages, disadvantages, and pitfalls; provide an introduction to NGS data analysis software and pipelines; present practical utilization and clinical examples of NGS in daily practice in hematologic neoplasms and solid tumors; and give an introduction to advanced technology and approaches in NGS, including RNA sequencing, detection of fusion genes, and detection of structural abnormalities.

The event will be hosted by Maher Albitar, MD, NeoGenomics’ senior vice president, chief medical officer, and director of research and development. Speaking at the symposium are Razelle Kurzrock, MD, chief, Division of Hematology and Oncology, University of San Diego School of Medicine, and director of the Center for Personalized Cancer Therapy and of the clinical trials office at UCSD Moores Cancer Center; and Guillermo Garcia-Manero, MD, deputy chair of translational research and professor, Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston.

The link to the registration can be found at http://bit.ly/2BzhD1x.

More top news


Check Also

NeoGenomics acquires Clarient, 12/15

December 2015—NeoGenomics has reached an agreement to acquire Clarient and its wholly owned subsidiary Clarient Diagnostic Services. Clarient, a unit of GE Healthcare’s Life Sciences business, is based in Houston and in Aliso Viejo, Calif., and has approximately 415 employees. Clarient had 2014 revenue of $127 million.